Type 1 diabetes in adults. National clinical guideline for diagnosis and management in primary and secondary care

GUIDELINE TITLE
Type 1 diabetes in adults. National clinical guideline for diagnosis and management in primary and secondary care.

BIBLIOGRAPHIC SOURCE(S)
National Collaborating Centre for Chronic Conditions. Type 1 diabetes in adults. National clinical guideline for diagnosis and management in primary and secondary care. London (UK): Royal College of Physicians; 2004. 171 p. [382 references]

GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

February 26, 2009 - Reglan (metoclopramide): The U.S. Food and Drug Administration (FDA) notified healthcare professionals that manufacturers of metoclopramide, a drug used to treat gastrointestinal disorders, must add a boxed warning to their drug labels about the risk of its long-term or high-dose use.
December 16, 2008 - Antiepileptic drugs: The U.S. Food and Drug Administration (FDA) has completed its analysis of reports of suicidality (suicidal behavior or ideation [thoughts]) from placebo-controlled clinical trials of drugs used to treat epilepsy, psychiatric disorders, and other conditions. Based on the outcome of this review, FDA is requiring that all manufacturers of drugs in this class include a Warning in their labeling and develop a Medication Guide to be provided to patients prescribed these drugs to inform them of the risks of suicidal thoughts or actions. FDA expects that the increased risk of suicidality is shared by all antiepileptic drugs and anticipates that the class labeling change will be applied broadly.


abrir aquí para acceder al documento NGC AHRQ completo:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=6249&nbr=004009&string=